

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(currently amended):** An isolated protein comprising:
 - a) the 4- α -helix bundle motif formed from the α -helices of the ROP (repressor of primer) of SEQ ID NO:11 and
 - b) a redox centre,
wherein the redox centre comprises a ~~metal atom which is stable in different oxidation states~~ haem group.
2. **(canceled).**
3. **(previously presented):** The protein of Claim 1, wherein the redox centre is bound to the protein, by coordination by one or more of histidine, leucine, methionine or cysteine residues.
4. **(previously presented):** The protein of Claim 1, wherein the redox centre is covalently bound to the 4- α -helix bundle motif formed from the α -helices of ROP.
5. **(original):** The protein of Claim 1 which has a redox mid-point potential in the range of -485 to +320mV.

6. **(withdrawn):** The protein of Claim 1 which has α -helix regions each having at least 60% similarity or identity with the α -helix regions of SEQ ID Nos: 1 and 3.
7. **(withdrawn):** The protein of claim 6, wherein said four α -helix regions are connected by loops.
8. **(withdrawn):** The protein of claim 7, wherein the four α -helices are joined in the order 1-1'-2'-2.
9. **(withdrawn):** The protein of Claim 1 which is formed by connecting two wild type ROP proteins to obtain the 4-helix bundle as one continuous polypeptide having at least 60% similarity or identity with SEQ ID No: 8.
10. **(withdrawn):** The protein of claim 9, wherein the histidine residues corresponding to H76, H78, H107 and H109 in sequence ID No. 8 are removed.
11. **(withdrawn):** The protein of claim 9, wherein histidine, leucine, methionine or cystein residues are introduced one or both positions corresponding to 56 and 113 in SEQ ID No: 8.
12. **(previously presented):** The protein of claim 1 which has a haem redox centre coordinated to the 4- α -helix bundle motif via two histidine residues.

13. (original): The protein of claim 12 which has a mid-point potential in the range -400mV to +300MV.

14. (canceled).

15. (previously presented): The protein of claim 1 which has a stability, measured as the unfolding free energy when denaturant is added to the protein of $\Delta G_{\text{obs}}\text{H}_2\text{O}$ is greater than or equal to y, wherein y is greater than or equal to 3.0 kcal/mol.

16. (withdrawn): A method of producing the protein of claim 1 comprising

- i) expressing all four α -helices as a single polypeptide chain;
- ii) engineering the required mutations to enable redox centre binding;
- iii) expressing and purifying, or producing the redox centre binding mutant;

and

- iv) incubating the mutant with an excess of the redox centre to produce the protein.

17. (withdrawn): A nucleotide sequence which encodes the protein of claim 1 or a fragment thereof.

18. (withdrawn): A vector comprising the nucleotide sequence of claim 17.

19-20. (canceled).

21. (previously presented): An apparatus comprising the protein of claim 1 associated with the electrode.

22. (original): An apparatus according to claim 21 wherein the protein is absorbed onto an electrode.

23. (withdrawn - currently amended): A protein according to claim ~~2~~1 in which the redox centre is an iron sulfur centre.

24.-25. (canceled).

26. (withdrawn): A protein according to claim 6 in which the α -helix regions each have at least 80% similarity or identity with the α -helix regions of SEQ ID No: 1.

27. (withdrawn): A protein according to claim 9 in which the continuous polypeptide has at least 80% similarity or identity with SEQ ID No: 8.